This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Clorox (CLX) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
Clorox (CLX) closed the most recent trading day at $124.04, moving -0.74% from the previous trading session.
Procter and Gamble Earnings: Can Strong Retail Sales Trigger a Beat?
by Ethan Feller
Just this morning we found out that US retail sales jumped 0.7% in September. Can this positive wave carry Procter and Gamble¿¿¿s earnings as well?
Can Clorox (CLX) Rebound on Pricing & Cost-Saving Efforts?
by Zacks Equity Research
Solid demand, pricing actions, cost-saving efforts and other growth strategies are likely to aid Clorox's (CLX) performance in the near future.
Clorox (CLX) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
Clorox (CLX) concluded the recent trading session at $123.11, signifying a -1.51% move from its prior day's close.
Company News for Oct 6, 2023
by Zacks Equity Research
Companies in The News Are: CAG, CLX, LW, PEP
Clorox (CLX) Unveils Preliminary Q1 Results, Hurt by Cyber Attack
by Zacks Equity Research
Clorox's (CLX) Q1 preliminary update reveals significant challenges due to a cybersecurity attack that disrupted its operations.
Clorox (CLX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Clorox (CLX) closed at $130.34, marking a -0.55% move from the previous day.
Energy Drinks & New Products Aid Monster Beverage (MNST) Sales
by Zacks Equity Research
Despite elevated costs, Monster Beverage's (MNST) continued momentum in the energy drinks category and robust new product pipeline will likely drive growth.
P&G (PG) Gains From Solid Product Portfolio, Pricing Actions
by Zacks Equity Research
Procter & Gamble (PG) stays afloat in a tough environment, thanks to its product portfolio, pricing actions, and productivity and cost-saving plans.
Clorox (CLX) Stock Moves -1.25%: What You Should Know
by Zacks Equity Research
Clorox (CLX) closed at $130.41 in the latest trading session, marking a -1.25% move from the prior day.
Here's Why Clorox (CLX) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Clorox (CLX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Clorox (CLX) closed the most recent trading day at $136.46, moving -1.43% from the previous trading session.
Company News for Sep 19, 2023
by Zacks Equity Research
Companies in The News Are: CLX,AAPL,F,GM
Clorox (CLX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Clorox (CLX) closed the most recent trading day at $147.35, moving -1.5% from the previous trading session.
Can Strategic Growth Efforts Aid Clorox (CLX) Amid High Costs?
by Zacks Equity Research
Despite inflation concerns, Clorox (CLX) looks well-poised to drive growth on solid demand, pricing actions, cost-saving efforts and other growth strategies.
How to Boost Your Portfolio with Top Consumer Staples Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Why Clorox (CLX) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 Stocks to Buy on Recent Dividend Hikes
by Derek Lewis
Dividend hikes reflect a company's commitment to returning value to shareholders, undoubtedly encouraging. And recently, all three of these companies have boosted their payouts.
Clorox (CLX) Surpasses Earnings & Sales Estimates in Q4
by Zacks Equity Research
Clorox's (CLX) Q4 results reflect gains from a solid product pipeline, improved pricing, cost savings and strong execution, offset by lower volume and inflation.
Clorox (CLX) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Clorox (CLX) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Clorox (CLX) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Clorox (CLX) delivered earnings and revenue surprises of 40.34% and 7.25%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's What Awaits Clorox (CLX) When It Reports Q4 Earnings
by Zacks Equity Research
Clorox's (CLX) Q4 results are expected to reflect gains from solid demand trends, pricing actions, digital investments, cost-saving efforts and the IGNITE strategy.
Church & Dwight (CHD) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Church & Dwight (CHD) delivered earnings and revenue surprises of 16.46% and 2.13%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Factors to Note Ahead of Sysco Corporation's (SYY) Q4 Earnings
by Zacks Equity Research
Sysco's (SYY) fiscal fourth-quarter earnings is likely to reflect gains from the Recipe for Growth initiative. However, rising cost inflation might have been a hurdle.
Nu Skin (NUS) Gears Up for Q2 Earnings: What's in Store?
by Zacks Equity Research
Nu Skin's (NUS) second-quarter 2023 performance will likely reflect macroeconomic challenges like rising global inflation. Also, unfavorable currency rates are a concern.